In this paper, we examine decision making in a spiking neuronal network and show that longer time constants for the inhibitory neurons can decrease the reaction times and produce theta rhythm. We analyze the mechanism and find that the spontaneous firing rate before the decision cues are applied can drift, and thereby influence the speed of the reaction time when the decision cues are applied. The drift of the firing rate in the population that will win the competition is larger if the time constant of the inhibitory interneurons is increased from 10 to 33 ms, and even larger if there are two populations of inhibitory neurons with time constants of 10 and 100 ms. Of considerable interest is that the decision that will be made can be influenced by the noise-influenced drift of the spontaneous firing rate over many seconds before the decision cues are applied. The theta rhythm associated with the longer time constant networks mirrors the greater integration in the firing rate drift produced by the recurrent connections over long time periods in the networks with slow inhibition. The mechanism for the effect of slow waves in the theta and delta range on decision times is suggested to be increased neuronal spiking produced by depolarization of the membrane potential on the positive part of the slow waves when the neuron's membrane potential is close to the firing threshold.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634784 | PMC |
http://dx.doi.org/10.1523/JNEUROSCI.0945-10.2010 | DOI Listing |
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer. HER2-targeted therapies have shown clinical activity against these tumor types, resulting in regulatory approvals. However, the efficacy of HER2 therapies in tumors with HER2 mutations has not been widely investigated.
View Article and Find Full Text PDFPLOS Digit Health
January 2025
Johnson & Johnson Global Public Health, Janssen Pharmaceutica NV, Beerse, Belgium.
While the incidence of Human Immunodeficiency Virus (HIV) infection is decreasing in most age groups worldwide, it is rising among adolescents and young adults, who also face a higher rate of HIV-related deaths. This tech-savvy demographic may benefit from an online patient portal designed to enhance patient activation-empowering them to manage their health independently. However, the effectiveness of such digital health interventions on young HIV patients in Kenya remains uncertain.
View Article and Find Full Text PDFJ Neurophysiol
January 2025
School of Kinesiology, Faculty of Health Sciences, The University of Western Ontario, London, ON, Canada.
The purpose was to assess whether visual feedback of torque contributes to motor unit (MU) firing rate reduction observed during post-activation potentiation (PAP) of skeletal muscle. From 15 participants 23 MUs were recorded with intramuscular fine-wire electrodes from the tibialis anterior during isometric dorsiflexion contractions at 20% of maximum, with and without both PAP and visual feedback of torque. A 5s maximal voluntary contraction (MVC) was used to induce PAP, and evoked twitch responses were assessed before and after.
View Article and Find Full Text PDFArch Orthop Trauma Surg
January 2025
Department of Trauma and Orthopaedic Surgery, Cologne Merheim Medical Center, Witten/Herdecke University, Colone, Germany.
Background: Traumatic hip dislocations are associated with high morbidity and overall limitations of daily living activities. Residual disability inhibits returning to work after severe injuries and minimizes financial independence and social involvement, which are both related to well-being and good health. The aim of this study was to analyze epidemiological and socioeconomic status following traumatic hip dislocations to identify predictors for return to work.
View Article and Find Full Text PDFJ Neurol
January 2025
Department of Neurology, Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Background: Natalizumab (NAT) is an established disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, its use involves complex decision-making, often leading to initial use of lower efficacy therapies. Recently, the first biosimilar NAT was approved, enabling competitive pricing.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!